Pair page
Decapeptide-12 with Nonapeptide-1
Mechanism-tag overlap and published literature for Decapeptide-12 and Nonapeptide-1, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
tyrosinase-inhibitor
cosmetic-peptide
brighteningmc1r-antagonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Decapeptide-12 and Nonapeptide-1 have published these mechanism-level observations. Not a co-administration recommendation.
Nonapeptide-1 is an α-MSH / MC1R antagonist — mechanistically upstream of decapeptide-12's enzyme-level inhibition. Pairing an MC1R-axis antagonist with a direct tyrosinase inhibitor addresses two different levels of the melanogenesis cascade (signaling and catalysis) and is the cleanest theoretical stack within cosmetic peptides. Clinical head-to-head data remain limited.
A direct mushroom-tyrosinase-inhibitory peptide with published human melasma data (Hantash and Jimenez 2009, 2012). Nonapeptide-1 shuts down the MC1R→cAMP→MITF→tyrosinase transcription upstream; decapeptide-12 inhibits the tyrosinase enzyme itself at the downstream endpoint. The two peptides stack mechanistically distinct steps and are formulated together in some commercial brightening systems. Both are peptide-scale ingredients with favorable tolerability versus hydroquinone.
Quick facts
Decapeptide-12
Nonapeptide-1
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2018 | Decapeptide-12 | Jiang L, Hino PD, Bhatia A, Stephens TJ, Jimenez F. Efficacy of Trifecting Night Cream, a novel triple-acting skin brightening product: a double-blind, placebo-controlled clinical study. J Clin Aesthet Dermatol. 2018;11(12):25-30. (Envy Medical triple-action cream containing dec… | human trial |
| 2009 | Decapeptide-12 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663110. (Pivotal split-face RCT pilot in five Fitzpatrick IV fema… PMID 19663110 | human trial |
| 2013 | Decapeptide-12 | Ramírez SP, Carvajal AC, Salazar JC, Arroyave G, Flórez AM, Echeverry HF. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma. J Drugs Dermato… PMID 23839199 | human pilot |
| 2012 | Decapeptide-12 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527440. (Open-label evaluation of the full Lumixyl brightening system in mild-to-moderate facial melasma.) PMID 22527440 | human pilot |
| 2012 | Decapeptide-12 | Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12 (24-week photodamage study). J Drugs Dermatol. 2012. PMID: 22401652. (24-week open-label in photodamaged facial hyperpigmentation; subset-shift improvements in grade-4 severe… PMID 22401652 | human pilot |
| 2012 | Decapeptide-12 | Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012;38(7 Pt 1):971-984. PMID: 22583339. (Hantash-co-authored contemporary melasma-therapeutics review that situates decapeptide-12 within the broader depigmentin… PMID 22583339 | human study |
| 2019 | Decapeptide-12 | Hantash BM, Abu Ubeid A. Tyrosinase inhibitors with potent anti-senescence activity in human neonatal keratinocyte progenitors. 2019. (Extends decapeptide-12 mechanistic claims into SIRT-pathway anti-senescence in human keratinocytes — supports "brightening plus anti-aging" posi… | preclinical, in vitro |
| 2009 | Decapeptide-12 | Abu Ubeid A, Zhao L, Wang Y, Hantash BM. Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. 2009;129(9):2242-2249. PMID: 19440221. (Foundational discovery paper — phage-display biopanning that identified decapeptide-12… PMID 19440221 | preclinical, in vitro |
| 1993 | Decapeptide-12 | Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100(6):806-811. (Classic determinant-of-pigmentation paper establishing tyrosinase as the rate-limiting enzyme o… | preclinical, in vitro |
| 2016 | Decapeptide-12 | Ochiai A, Tanaka S, Tanaka T, Taniguchi M. New tyrosinase inhibitory decapeptide: molecular insights into the role of tyrosine residues. J Biosci Bioeng. 2016;121(6):607-613. (Independent decapeptide-class tyrosinase-inhibitor work highlighting the role of tyrosine residues in t… | mechanism / discovery |
| 2012 | Decapeptide-12 | Ubeid AA, Do S, Nye C, Hantash BM. Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides. Biochim Biophys Acta. 2012;1820(10):1481-1489. (Extended structure-activity work from the Hantash group on the peptide-tyrosinase inhibitor scaffold.) | mechanism / discovery |
| 2014 | Decapeptide-12 | Ubeid AA, Hantash BM. Minireview: Peptide analogs and short sequence oligopeptides as modulators of skin pigmentation. Curr Top Med Chem. 2014;14(12):1418-1424. PMID: 24894693. (Review of tyrosinase-inhibitor oligopeptides and α-MSH analogs in cosmetic and dermatologic pigment m… PMID 24894693 | review |
| 2019 | Nonapeptide-1 | Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: A systematic review of randomized controlled trials. J Drugs Dermatol. 2019;18(11):1156-1163. PMID: 31741361. (Systematic review of RCT evidence for topical melasma treatments — the evidence-quality benchmark that no… PMID 31741361 | systematic review |
| 2009 | Nonapeptide-1 | Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. 2009;8(8):732-735. PMID: 19663111. (Decapeptide-12 melasma pilot — the closest published pep… PMID 19663111 | human trial |
| 2012 | Nonapeptide-1 | Hantash BM, Jimenez F. Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system. J Drugs Dermatol. 2012;11(5):660-662. PMID: 22527433. (Follow-up decapeptide-12 melasma open-label trial — the peptide brightener with the most published independent… PMID 22527433 | human pilot |
| 1999 | Nonapeptide-1 | Abdel-Malek Z, Suzuki I, Tada A, Im S, Akcali C. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci. 1999;885:117-133. PMID: 10816645. (Review of MC1R biology in human cutaneous pigmentation.) PMID 10816645 | human study |
| 1995 | Nonapeptide-1 | Kameyama K, Sakai C, Kuge S, Nishiyama S, Tomita Y, Ito S, Wakamatsu K, Hearing VJ. The expression of tyrosinase, tyrosinase-related proteins 1 and 2 (TRP1 and TRP2), the silver protein, and a melanogenic inhibitor in human melanoma cells of differing melanogenic activities. Pig… PMID 7659683 | human study |
| 1995 | Nonapeptide-1 | Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ. Nle4DPhe7 alpha-melanocyte-stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes. J Invest Dermatol. 1995;104(1):83-85. PMID: 7798647. (NDP-MSH / melanotan-I demonstration of agonist-driven eume… PMID 7798647 | preclinical, in vitro |
| 2012 | Nonapeptide-1 | Kadekaro AL, Chen J, Yang J, Chen S, Jameson J, Swope VB, Cheng T, Kadakia M, Abdel-Malek Z. Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol Cancer Res. 2012;10(6):778-786. PMID: 22622028. (Docum… PMID 22622028 | mechanism / discovery |
| 1996 | Nonapeptide-1 | Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology. 1996;137(5):1627-1633. PMID: 8612494. (Original characterization of α-MSH / ACT… PMID 8612494 | mechanism / discovery |
| 1994 | Nonapeptide-1 | Kobayashi T, Urabe K, Winder A, Jiménez-Cervantes C, Imokawa G, Brewington T, Solano F, García-Borrón JC, Hearing VJ. Tyrosinase related protein 1 (TRP1) functions as a DHICA oxidase in melanin biosynthesis. EMBO J. 1994;13(24):5818-5825. PMID: 7813420. (Functional characterizat… PMID 7813420 | mechanism / discovery |
| 1992 | Nonapeptide-1 | Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11(2):519-526. PMID: 1537333. (Original characterization of TRP-2 / DCT as the dopachrome tautomerase — part… PMID 1537333 | mechanism / discovery |
| 2025 | Nonapeptide-1 | Austin E, Geisler AN, Nguyen J, Kohli I, Hamzavi I, Lim HW, Jagdeo J. Peptide design for enhanced anti-melanogenesis: Optimizing molecular weight, polarity, and cyclization. Int J Cosmet Sci. 2025;47(1):37-52. PMID: 39896936. (Recent review of anti-melanogenic peptide design pri… PMID 39896936 | review |
| 2021 | Nonapeptide-1 | Herraiz C, Martínez-Vicente I, Maresca V. The α-melanocyte-stimulating hormone/melanocortin-1 receptor interaction: A driver of pleiotropic effects beyond pigmentation. Pigment Cell Melanoma Res. 2021;34(4):748-761. PMID: 33884776. (Current comprehensive review of α-MSH/MC1R sig… PMID 33884776 | review |
Related pair pages
More research context
Frequently asked
Have Decapeptide-12 and Nonapeptide-1 been studied together?
Researchers have published mechanistic-level co-administration discussion of Decapeptide-12 and Nonapeptide-1. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Decapeptide-12 and Nonapeptide-1 share?
Decapeptide-12 and Nonapeptide-1 share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Decapeptide-12 and Nonapeptide-1?
Decapeptide-12: Cosmetic ingredient. Nonapeptide-1: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Decapeptide-12 and Nonapeptide-1?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Decapeptide-12 profile and the Nonapeptide-1 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026